Back to top
more

XOMA Royalty Corporation (XOMA)

(Delayed Data from NSDQ)

$30.97 USD

30.97
23,669

+0.77 (2.55%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $30.89 -0.08 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

by Zacks Equity Research

Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

    EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down

    by Zacks Equity Research

    Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.

      Anthera's Sollpura Strong on Positive Futility in Phase III

      by Zacks Equity Research

      Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

        Regeneron's Dupixent Receives MHLW Nod for Label Expansion

        by Zacks Equity Research

        Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

          Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

          by Zacks Equity Research

          Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).

            Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%

            by Zacks Equity Research

            Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares nearly 9% on the day amid huge volumes.

              Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

              by Zacks Equity Research

              Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

                Arpita Dutt headshot

                3 Pharma and Biotech Stocks to Watch Out for in 2018

                by Arpita Dutt

                Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

                  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

                  by Zacks Equity Research

                  The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.

                    Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

                    by Zacks Equity Research

                    We look at the factors that drive the share price of Perrigo to a 52-week high.

                      Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU

                      by Zacks Equity Research

                      Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.

                        Why is Novo Nordisk Stock Up More Than 50% in Past Year?

                        by Zacks Equity Research

                        We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.

                          Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up

                          by Zacks Equity Research

                          Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.

                            Acorda's Shares Down on Disappointing Ampyra View for 2018

                            by Zacks Equity Research

                            Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.

                              Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

                              by Zacks Equity Research

                              Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

                                Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

                                by Zacks Equity Research

                                Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

                                  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines

                                  by Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines

                                    4 Biotech Stocks to Watch in the New Year

                                    by Zacks Equity Research

                                    We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.

                                      Emergent Starts Phase II Study on Anti-influenza Candidate

                                      by Zacks Equity Research

                                      Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.

                                        United Therapeutics (UTHR) Collaborates With Corsair Pharma

                                        by Zacks Equity Research

                                        United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.

                                          Pfizer (PFE) Collaborates With Sangamo for Gene Therapy

                                          by Zacks Equity Research

                                          Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.

                                            New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails

                                            by Zacks Equity Research

                                            Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.

                                              Thermo Fisher Buys Phenom-World, Aids Analytical Instruments

                                              by Zacks Equity Research

                                              On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.

                                                Inovio Amends Chinese Deal for Immunotherapy, Shares Up

                                                by Zacks Equity Research

                                                Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.

                                                  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy

                                                  by Zacks Equity Research

                                                  Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.